News Column

ALNYLAM PHARMACEUTICALS, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers

July 2, 2014

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 1, 2014, the Board of Directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Company") elected Amy W. Schulman as a Class III director with a term expiring at the annual meeting of stockholders to be held in 2016.

In connection with her election to the Board, Ms. Schulman received a stock option to purchase 30,000 shares of common stock of the Company, vesting annually over three years, and will be compensated as a director pursuant to the Company's compensation policy for non-employee directors, which is described in the Company's Proxy Statement for the 2014 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 29, 2014.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters